AppELT, S.: Regular items approved before patent expiration: Incentive re -evaluation of independent general items. Munich disc. pap. 235 (2010)
Google Academic Search
AppELT, S.: Regular items approved before patent expiration: Incentive re -evaluation of independent general items. Pastor Econ. statistics 97(3), 654–666 (2015)
Google Academic Search
Bairoliya, N., Karacamandic, P., McCullough, JS, Petrin, A. Nber Working Papers (2017)
Berndt, ER, Mortimer, R. Health AFF. 26(3), 790–799 (2007)
Google Academic Search
Berndt, ER, Mortimer, R., Parece, A.: Is the accredited generic drug interfering with the paragraph IV certification? Recent evidence. Analysis Group Inc., Working Paper (2007)
Chen, T.: Certified Generic: Hatch Rocks Far Reform. VA. L. Rev. 93459 (2007)
Google Academic Search
Cheng, N., Banerjee, T., Qian, J., Hansen, Ra: General Marketing Association, which is approved and approved for prescription medicine expenditures for antidepressants from 2000 to 2011. J. am. Pharmaceutical. association. 57(3), 341–348 (2017)
Google Academic Search
COLGAN, S., FAASSE, K., Martin, LR, Stephens, MH, Grey, A., Petrie, KJ: Awareness of the general drugs of the general population, doctors and pharmacists: systematic review. BMJ open 5(12), E008915 (2015)
Google Academic Search
Cook, a. : The price and profits of the pharmaceutical industry have influenced how competition from generic drugs has increased. US Government Printing Office (1998)
Crawford, S. (2005). Uncertainty and learning of pharmaceutical demand. Econometrica 1137–1173
Danzon, PM, & Furukawa, MF: Evidence of General Pharmaceuticals: Pharmacy vs. Doctor -centered market (Tech. Rep.). National Economic Research Bureau (2011)
Ellison, G., Ellison, SF: Strategic entry inhibition and pharmaceuticals before patent expiration. morning. Econ. J. Microecon. 3(1), 1–36 (2011)
Google Academic Search
Federal Trade Commission et al. : Approved generic: Temporary report of the Federal Trade Commission, June (2010)
Federal Trade Commission et al. : Approved generic drug: short -term effect and long -term impact: Federal Trade Commission Report (2011)
Feng, a. : History dependence on drug demand: Identification and implications for incentives. Econo Pastor. statistics 21–15 (2024)
Google Academic Search
Frank, S. (1997). Pharmaceutical and Pharmaceutical Price. Economic and Management Strategy Journal 75–90
Grabowski, HG, Vernon, JM: In the 1980s, we return to R & D to the introduction of new drugs. J. Health Econ. 13(4), 383–406 (1994)
Google Academic Search
Greene, JA, Kesselheim, As: Why do the same medicine look different? Pills, trade outfits and public health. N. English. J. Med. 365(1), 83 (2011)
Google Academic Search
HANCOCK, J., & Lupkin, S.: A method of becoming a master to produce approved generics by pharmaceutical companies. Kevinmed.com (2019)
Hansen, Ra, Qian, J., Berg, R., Linneman, J., SEOANE-VAZQUEZ, E., Dutcher, S., PEISSIG, P. In: Pharmacology and Pharmaceutical Safety (Vol. 25, pp. 355–356) (2016)
HASSETT, KA, Shapiro, RJ: The effect of the approved general pharmaceuticals on the introduction of other general pharmaceuticals. SONECON, LLC (2007)
HOLLIS, A.: The radial effect of the brand control “doctor generator” in the Canadian pharmaceutical market. Canadian Public Policy/Analyze de Politiques pp.21–32 (2003)
Hollis, a. : How does the brand’s “Own Generics” affect the pharmaceutical price? 27(4), 329–350 (2005)
Hollis, A., Liang, BA: Evaluation of the approved generic effect on consumer prices. J. Biolaw bus. 10(1), 10 (2007)
Google Academic Search
HUDSON, J.: A general takes up in the pharmaceutical market after the expiration of the patent: multilingual study. int. Pastor for court. 20(2), 205–221 (2000)
Google Academic Search
Hurwitz, MA, Caves, Re: Persuasion or information? Stocks of promotions and brands and generic pharmaceuticals. J. Law Econ. 31(2), 299–320 (1988)
Google Academic Search
Janssen, A.: General and Brand Pharmaceutical Price: Competition for conversion costs. Econ. J. 21937–1967 (2023)
Google Academic Search
Kilian, L., MURPHY, D.: Reasons for unofficial signal restrictions: Understanding the epidemiology of the petroleum market VAR model. J. Eur. Econ. association. 851166–1188 (2012)
Google Academic Search
KONG, Y., SELDON, JR: Pseudo-Generic products and pharmaceutical market entry barriers. IND. ORGAN Pastor. 25(1), 71–86 (2004)
Moreno-Torres, I., Puig-Junoy, J., Borell, JR: General entry into the regulated Spanish pharmaceutical market. IND. ORGAN Pastor. 34(4), 373–388 (2009)
Morton, FMS: Tech. National Bureau of Economic Research (REP) (1997)
Regan, TL: General input, price competition and market segmentation of the prescription market. int. J. IND. Organ. 26(4), 930–948 (2008)
Google Academic Search
REIFFEN, D., WARD, MR: ‘Brand Generic’ as a strategy to limit the cannibalization of the pharmaceutical market. management. decision. Econ. 28(4–5), 251–265 (2007)
Google Academic Search
SAHA, A., Grabowski, H., Birnbaum, H., Greenberg, P., Bizan, O.: General competition in the US pharmaceutical industry. int. J. Econ. bus. 13(1), 15–38 (2006)
Google Academic Search
Song, Y., & Barthol, D.: Unpaired Power: How does drug replacement affect the patient’s demand for ordinary drugs? Social Sci -fi science. former. PUBL. (2016)
European Commission: Preliminary Report on Pharmaceutical Survey. DG Competition Employees Practice Thesis (2008)
Wiedermann, W., Zhang, B., Shi, D.: Heterogeneity detection in the causal relationship direction: model -based recursive approach. action. Coastal behavior 22711–2730 (2024)
Google Academic Search
Wilde, J.: Identification of a multi -equipped professional combination model with endurance dummy regression. Econ. Lett. 69(3), 309–312 (2000)
Google Academic Search
